Alexion Pharmaceuticals, Inc. (ALXN): Price and Financial Metrics
Alexion Pharmaceuticals, Inc. (ALXN)
Today's Latest Price: $120.51 USD
Updated Dec 4 4:00pm
Add ALXN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
ALXN Stock Summary
- ALXN has a market capitalization of $26,863,276,778 -- more than approximately 91.94% of US stocks.
- Of note is the ratio of Alexion Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; just 15.11% of US stocks have a lower such ratio.
- As for revenue growth, note that ALXN's revenue has grown 23.79% over the past 12 months; that beats the revenue growth of 81.62% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Alexion Pharmaceuticals Inc are SLB, VIPS, CHA, PCAR, and ZBRA.
- Visit ALXN's SEC page to see the company's official filings. To visit the company's web site, go to www.alexion.com.
ALXN Stock Price Chart Interactive Chart >
ALXN Price/Volume Stats
| Current price | $120.51 | 52-week high | $128.57 |
| Prev. close | $121.06 | 52-week low | $72.67 |
| Day low | $119.40 | Volume | 1,012,300 |
| Day high | $121.45 | Avg. volume | 2,135,417 |
| 50-day MA | $121.19 | Dividend yield | N/A |
| 200-day MA | $107.83 | Market Cap | 26.37B |
Alexion Pharmaceuticals, Inc. (ALXN) Company Bio
Alexion Pharmaceuticals a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company was founded in 1992 and is based in Cheshire, Connecticut.
ALXN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $120.51 | $393.4 | 220% |
We started the process of determining a valid price forecast for Alexion Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Alexion Pharmaceuticals Inc ranked in the 71th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 222% on a DCF basis. The most interesting components of our discounted cash flow analysis for Alexion Pharmaceuticals Inc ended up being:
- As a business, ALXN is generating more cash flow than 87.01% of positive cash flow stocks in the Healthcare.
- ALXN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 36.99% of tickers in our DCF set.
- Alexion Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 214% |
| 1% | 217% |
| 2% | 220% |
| 3% | 224% |
| 4% | 227% |
| 5% | 230% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ALXN, try ABBV, FTLF, ARA, HUM, and SGRY.
Loading social stream, please wait...